Hans K. Erickson

Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing

Hans K. Erickson, Peter U. Park, Wayne C. Widdison et al. · Cancer Research · 2006 · 566 citations · Full text

Immunology, Immunotherapy, Cancer Biology +19

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Yelena Kovtun, Charlene A. Audette, Michele Mayo et al. · Cancer Research · 2010 · 254 citations

Immunology, Immunotherapy, Tumor Biology +18

Effects of Drug–Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody–Maytansinoid Conjugates

Xiuxia Sun, Jose F. Ponte, Nicholas C. Yoder et al. · Bioconjugate Chemistry · 2017 · 242 citations

Engineering, Immunology, Pharmacotherapy +23

Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates

Hans K. Erickson, Wayne C. Widdison, Michele Mayo et al. · Bioconjugate Chemistry · 2009 · 238 citations

Engineering, Immunology, Immunotherapeutics +19

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold et al. · Molecular Cancer Therapeutics · 2012 · 191 citations

Vitro Potency, Immunology, Pharmacotherapy +19